Based on Endpoints Signal Pulse Report | December 2025
A new Signal Pulse Report from Endpoints News reveals that artificial intelligence has become deeply embedded across biopharma workflows, with nearly half of industry professionals now identifying as heavy AI users—a shift that is reshaping expectations for the future of drug research and development.
According to the report, which surveyed 441 verified Endpoints News readers, 48% of respondents said they use AI extensively or frequently in their work. While many participants described AI’s current impact as modest, expectations rise sharply when looking ahead: three-quarters believe AI will fundamentally transform drug R&D by 2030, and heavy users are especially confident that change is already underway.
Endpoints Signal found a clear divide between heavy and light AI users. Professionals who rely on AI tools regularly reported more tangible workflow improvements, greater confidence in long-term impact, and fewer concerns around implementation challenges. In contrast, light users were more skeptical, citing hype, integration hurdles, and unclear value.
The report highlights that the most significant barriers to AI adoption are not computing power or leadership support, but rather the difficulty of translating models into real-world biology and gaining access to high-quality, usable biological data. Workflow integration ranked as the third-largest obstacle.
Endpoints News also reported that optimism around AI’s future is reinforced by major industry investments and collaborations in 2025, including large-scale computing initiatives, shared protein data efforts, and multi-billion-dollar AI partnerships across big pharma.
While established pharmaceutical companies benefit from deep data resources and capital, respondents also noted that technology companies entering healthcare could emerge as influential players by owning critical software, infrastructure, and model layers.
The findings suggest that AI’s impact in biopharma will not arrive as a single disruptive moment, but through gradual, cumulative change—one that is already visible to those most deeply engaged with the tools.
This media release is based entirely on reporting and analysis published by Endpoints News and its intelligence platform, Endpoints Signal, including the December 2025 Signal Pulse Report authored by Tom Randall, VP of Endpoints News and Head of Signal.
By